KEITH REMO: Open Payments
NPI 1952409203 · NEW BRAUNFELS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,689 in 109 payments from 20 companies in 2025. Trend: 2023 $1,660 · 2024 $2,309 · 2025 $2,689
Food & beverage: $2,491Education: $198
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 23 | $681 |
| UCB, Inc. | 13 | $503 |
| Regeneron Healthcare Solutions, Inc. | 10 | $274 |
| Galderma Laboratories, L.P. | 19 | $239 |
| Lilly USA, LLC | 5 | $206 |
| PFIZER INC. | 6 | $116 |
| ABBVIE INC. | 4 | $94 |
| Novartis Pharmaceuticals Corporation | 5 | $87 |
| Kerecis Limited | 3 | $84 |
| GENZYME CORPORATION | 3 | $62 |
Products named: TREMFYA, Bimzelx, DUPIXENT, NEMLUVIO, CIBINQO, LIBTAYO, Kerecis SurgiClose, EBGLYSS.
Industry payments across TX — which companies pay providers there.
